Cumberland Pharmaceuticals Inc.
CPIX
$4.76
$0.235.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 36.54M | 34.75M | 35.75M | 36.79M | 37.51M |
| Total Other Revenue | 1.33M | 2.04M | 2.04M | 2.04M | 2.04M |
| Total Revenue | 37.87M | 36.79M | 37.79M | 38.83M | 39.55M |
| Cost of Revenue | 6.59M | 6.14M | 6.58M | 6.39M | 6.07M |
| Gross Profit | 31.28M | 30.65M | 31.20M | 32.43M | 33.49M |
| SG&A Expenses | 28.15M | 28.80M | 28.81M | 28.85M | 29.10M |
| Depreciation & Amortization | 4.75M | 4.48M | 4.58M | 4.64M | 4.76M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.30M | 44.21M | 45.38M | 45.37M | 45.76M |
| Operating Income | -6.43M | -7.43M | -7.60M | -6.55M | -6.21M |
| Income Before Tax | -6.47M | -10.78M | -10.32M | -8.36M | -6.29M |
| Income Tax Expenses | -22.80K | 59.20K | 54.70K | 50.20K | 45.70K |
| Earnings from Continuing Operations | -6.44 | -10.84 | -10.37 | -8.41 | -6.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -36.10K | -26.30K | -5.30K | -12.30K | 51.40K |
| Net Income | -6.48M | -10.87M | -10.38M | -8.42M | -6.28M |
| EBIT | -6.43M | -7.43M | -7.60M | -6.55M | -6.21M |
| EBITDA | -1.53M | -2.79M | -2.83M | -1.72M | -1.27M |
| EPS Basic | -0.46 | -0.77 | -0.73 | -0.60 | -0.44 |
| Normalized Basic EPS | -0.30 | -0.34 | -0.32 | -0.24 | -0.14 |
| EPS Diluted | -0.47 | -0.78 | -0.74 | -0.60 | -0.45 |
| Normalized Diluted EPS | -0.30 | -0.34 | -0.32 | -0.24 | -0.14 |
| Average Basic Shares Outstanding | 56.24M | 56.43M | 56.66M | 56.93M | 57.19M |
| Average Diluted Shares Outstanding | 56.24M | 56.43M | 56.66M | 57.09M | 57.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |